
1. Science. 2020 Aug 21;369(6506):936-942. doi: 10.1126/science.aax0701.

Cross-reactivity between tumor MHC class I-restricted antigens and an
enterococcal bacteriophage.

Fluckiger A(1)(2), Daillère R(1)(2)(3), Sassi M(4), Sixt BS(5)(6)(7)(8)(9)(10),
Liu P(6)(7)(8)(9)(10), Loos F(6)(7)(8)(9)(10), Richard C(11)(12)(13), Rabu
C(14)(15), Alou MT(1)(2)(16), Goubet AG(1)(2), Lemaitre F(1)(3), Ferrere G(1)(2),
Derosa L(1)(2)(17), Duong CPM(1)(2), Messaoudene M(18), Gagné A(18), Joubert
P(18), De Sordi L(19)(20), Debarbieux L(19), Simon S(14)(15), Scarlata CM(21),
Ayyoub M(21), Palermo B(22), Facciolo F(23), Boidot R(24), Wheeler R(25), Boneca 
IG(25), Sztupinszki Z(26), Papp K(27), Csabai I(27), Pasolli E(28), Segata N(29),
Lopez-Otin C(7)(8)(9)(10)(30), Szallasi Z(26)(31)(32)(33), Andre F(34)(35), Iebba
V(1)(2)(36), Quiniou V(37)(38), Klatzmann D(37)(38), Boukhalil J(16), Khelaifia
S(16), Raoult D(16), Albiges L(1)(39), Escudier B(1)(39)(40), Eggermont A(1)(41),
Mami-Chouaib F(42), Nistico P(22)(23), Ghiringhelli F(43), Routy B(18)(44),
Labarrière N(14)(15), Cattoir V(4)(45)(46), Kroemer
G(47)(7)(8)(9)(10)(48)(49)(50)(51), Zitvogel L(52)(2)(17)(50).

Author information: 
(1)Gustave Roussy Cancer Campus (GRCC), Villejuif, France.
(2)Institut National de la Santé et de la Recherche Médicale, U1015, Institut
Gustave Roussy, Villejuif, France.
(3)everImmune, Gustave Roussy Cancer Center, Villejuif, France.
(4)Université Rennes 1, Laboratoire de Biochimie Pharmaceutique, Inserm U1230 -
UPRES EA 2311, Rennes, France.
(5)Laboratory for Molecular Infection Medicine Sweden, Umeå Centre for Microbial 
Research, Department of Molecular Biology, Umeå University, 90187, Umeå, Sweden.
(6)Cell Biology and Metabolomics Platforms, Gustave Roussy Cancer Campus,
Villejuif, France.
(7)Equipe 11 labellisée Ligue contre le Cancer, Centre de Recherche des
Cordeliers, Paris, France.
(8)INSERM U1138, Paris, France.
(9)Université de Paris, Paris, France.
(10)Sorbonne Université, Paris, France.
(11)Research Platform in Biological Oncology, Dijon, France.
(12)GIMI Genetic and Immunology Medical Institute, Dijon, France.
(13)University of Burgundy-Franche Comté, Dijon, France.
(14)CRCINA, INSERM, Université d'Angers, Université de Nantes, Nantes, France.
(15)LabEx IGO "Immunotherapy, Graft, Oncology," Nantes, France.
(16)UMR MEPHI, Aix-Marseille Université, IRD, AP-HM, Institut
Hospitalo-Universitaire Méditerranée-Infection, 19-21 Boulevard Jean Moulin,
13385, Marseille cedex 05, France.
(17)Université Paris-Saclay, Villejuif, F-94805, France.
(18)Institut Universitaire de Cardiologie et de Pneumologie de Québec, Research
Center and Department of Cytology and Pathology, Québec City, Québec, Canada.
(19)Bacteriophage, Bacterium, Host Laboratory, Institut Pasteur, F-75015 Paris,
France.
(20)Sorbonne Université, Centre de Recherche Saint Antoine, INSERM UMRS_938,
Paris, France.
(21)Cancer Research Centre of Toulouse, INSERM UMR 1037, 31037 Toulouse, France; 
Université Toulouse III Paul Sabatier, 31330 Toulouse, France; Institut
Universitaire du Cancer de Toulouse-Oncopole, 31100 Toulouse, France.
(22)Unit of Tumor Immunology and Immunotherapy, Department of Research, Advanced 
Diagnostics and Technological Innovation, IRCCS Regina Elena National Cancer
Institute, Rome, Italy.
(23)Thoracic Surgery Unit, Department of Surgical Oncology, IRCCS Regina Elena
National Cancer Institute, Rome, Italy.
(24)Unit of Molecular Biology, Department of Biology and Pathology of Tumors,
Georges-François Leclerc Anticancer Center, UNICANCER, Dijon, France.
(25)Institut Pasteur, Unit Biology and Genetics of the Bacterial Cell Wall,
Paris, France.
(26)Computational Health Informatics Program (CHIP), Boston Children's Hospital, 
Boston, MA, USA.
(27)Department of Physics of Complex Systems, ELTE Eötvös Loránd University,
Budapest, Hungary.
(28)Department of Agricultural Sciences, University of Naples Federico II,
Naples, Italy.
(29)Department CIBIO, University of Trento, Trento, Italy.
(30)Departamento de Bioquímica y Biología Molecular, Instituto Universitario de
Oncología (IUOPA), Universidad de Oviedo, Oviedo, Spain.
(31)Harvard Medical School, Boston, MA, USA.
(32)Danish Cancer Society Research Center, Copenhagen, Denmark.
(33)MTA-SE-NAP, Brain Metastasis Research Group, 2nd Department of Pathology,
Semmelweis University, Budapest, Hungary.
(34)Department of Cancer Medicine, Breast Cancer Committee, Gustave Roussy,
Villejuif, France.
(35)INSERM Unit 981, Gustave Roussy, Villejuif, France.
(36)Department of Medical Sciences, University of Trieste, 34137 Trieste, Italy.
(37)AP-HP, Hôpital Pitié-Salpêtrière, Clinical Investigation Center in Biotherapy
(CIC-BTi) and Immunology-Inflammation-Infectiology and Dermatology Department
(3iD), F-75651, Paris, France.
(38)Sorbonne Université, INSERM, Immunology-Immunopathology-Immunotherapy (i3),
F-75651, Paris, France.
(39)Department of Medical Oncology, Gustave Roussy, Villejuif, France.
(40)INSERM U981, GRCC, Villejuif, France.
(41)Princess Maxima Center, CS 3584 Utrecht, the Netherlands.
(42)INSERM UMR 1186, Integrative Tumor Immunology and Immunotherapy, Gustave
Roussy, Fac. de Médecine - Univ. Paris-Sud, Université Paris-Saclay, 94805,
Villejuif, France.
(43)Department of Medical Oncology, Center GF Leclerc, Dijon, France.
(44)Division d'Hémato-Oncologie, Département de Médicine, Centre Hospitalier de
l'Université de Montréal (CHUM), Montréal, Québec, Canada.
(45)CHU de Rennes - Hôpital Ponchaillou, Service de Bactériologie-Hygiène
Hospitalière, Rennes, France.
(46)CNR de la Résistance aux Antibiotiques (laboratoire associé 'Entérocoques'), 
Rennes, France.
(47)Cell Biology and Metabolomics Platforms, Gustave Roussy Cancer Campus,
Villejuif, France. laurence.zitvogel@gustaveroussy.fr kroemer@orange.fr.
(48)Pôle de Biologie, Hôpital Européen Georges Pompidou, Assistance
Publique-Hôpitaux de Paris, Paris, France.
(49)Department of Women's and Children's Health, Karolinska University Hospital, 
1 Stockholm, Sweden.
(50)Suzhou Institute for Systems Biology, Chinese Academy of Medical Sciences,
Suzhou, China.
(51)Institut Universitaire de France, Paris, France.
(52)Gustave Roussy Cancer Campus (GRCC), Villejuif, France.
laurence.zitvogel@gustaveroussy.fr kroemer@orange.fr.

Intestinal microbiota have been proposed to induce commensal-specific memory T
cells that cross-react with tumor-associated antigens. We identified major
histocompatibility complex (MHC) class I-binding epitopes in the tail length tape
measure protein (TMP) of a prophage found in the genome of the bacteriophage
Enterococcus hirae Mice bearing E. hirae harboring this prophage mounted a
TMP-specific H-2Kb-restricted CD8+ T lymphocyte response upon immunotherapy with 
cyclophosphamide or anti-PD-1 antibodies. Administration of bacterial strains
engineered to express the TMP epitope improved immunotherapy in mice. In renal
and lung cancer patients, the presence of the enterococcal prophage in stools and
expression of a TMP-cross-reactive antigen by tumors correlated with long-term
benefit of PD-1 blockade therapy. In melanoma patients, T cell clones recognizing
naturally processed cancer antigens that are cross-reactive with microbial
peptides were detected.

Copyright © 2020 The Authors, some rights reserved; exclusive licensee American
Association for the Advancement of Science. No claim to original U.S. Government 
Works.

DOI: 10.1126/science.aax0701 
PMID: 32820119  [Indexed for MEDLINE]

